自2025年6月18日证监会主席吴清在陆家嘴论坛宣布重启科创板第五套上市标准以来，短短一个月内， 该标准下的药械企业IPO进程持续提速，为未盈利但具备创新潜力的药械企业打开了资本市场的大门。 上交所官网显示，上市审核委员会将在7月18日审核北芯生命的首发申请。这是科创板第五套上市标准 重启后第二家上会的药械企业。此前，禾元生物作为该标准重启后的首家药企已顺利过会，目前正处于 等待注册批文阶段。 值得注意的是，北芯生命的IPO冲刺早在2023年3月30日便已启动。彼时该公司递交科创板上市申请 后，历经两轮问询及长达27个月的审核等待，如今即将迎来"最后一关"的关键考验。 从融资方案看，北芯生命此次拟募资9.52亿元，其中3.82亿元用于介入类医疗器械产业化基地建设项 目，4.7亿元用于介入类医疗器械研发项目，1亿元用于补充流动资金。对比2023年3月首次披露的招股 书，公司原计划融资12.74亿元，此次不仅下调了募资规模，还取消了"营销网络建设项目"的投入。 有券商分析师向21世纪经济报道表示，从大环境看，近年来我国对真正具有创新能力药械企业的扶持力 度逐渐加大，包括融资多元化、税收政策利好、产学研紧密融合、人 ...

Core Viewpoint - Puang Medical Technology Co., Ltd. is preparing for an IPO on the Beijing Stock Exchange, having completed its guidance work with Guojin Securities as the advisory institution [2]. Financial Performance - In 2024, Puang Medical achieved operating revenue of 318.03 million yuan, representing a year-on-year increase of 34.61% [3]. - The net profit for the same period was 64.88 million yuan, up 41.34% compared to the previous year [3]. - The gross profit margin improved to 49.44%, compared to 47.20% in the previous year [3]. Shareholding Structure - The legal representative and chairman, Hu Chaoyu, directly holds 42,079 shares (0.10%) and indirectly controls 28.54% of the voting rights through Taiyouhong, 26.13% through Pumao Partnership, and 4.72% through Hangzhou Youying [4]. - Hu Chaoyu and his spouse, Mao Liuying, collectively control 59.49% of the voting rights, making them the actual controllers of the company [4]. Company Background - Puang Medical was established in January 2013, focusing on the research, production, and sales of diabetes care, general drug infusion, and minimally invasive medical devices [2]. - The registered capital of the company is 42.33 million yuan [2].